A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in <i>KRAS</i>-Mutant Colon Cancer Cells

Inoue, Akira; Mizushima, Tsunekazu; Wu, Xin; Okuzaki, Daisuke; Kambara, Nanami; Ishikawa, Sho; Wang, Jiaqi; Qian, Yamin; Hirose, Haruka; Yokoyama, Yuhki; Ikeshima, Ryo; Hiraki, Masayuki; Miyoshi, Norikatsu; Takahashi, Hidekazu; Haraguchi, Naotsugu; Hata, Taishi; Matsuda, Chu; Doki, Yuichiro; Mori, Masaki; Yamamoto, Hirofumi

doi:10.1158/1535-7163.mct-17-0850

Cited by 37 publications

(36 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their study revealed that miR‐4869 inhibits tumor cell proliferation by directly targeting KRAS and AKT. Inoue et al also reported that miR‐29b‐1‐5p is a TS‐miRNA and a passenger strand of miR‐29b‐3p. Compared with miR‐29b‐3p, miR‐29b‐1‐5p was significantly downregulated in K‐RAS mutant colon cancer patients.…”

Section: Delivery System Of Mirnamentioning

confidence: 96%

“…To improve the transduction efficacy of oligonucleotides, Hossain et al developed the carbonate apatite‐based delivery system. Using this system, several groups succeeded in the efficient transduction of TS‐miRNA into colon cancer cells . Hiraki et al identified miR‐4689 as a TS‐miRNA whose expression is downregulated by the K‐RAS mutant (KRAS G12V ).…”

Section: Delivery System Of Mirnamentioning

confidence: 99%

“…To improve the transduction efficacy of oligonucleotides, Hossain et al 93 developed the carbonate apatite-based delivery system. Using this system, several groups succeeded in the efficient transduction of TS-miRNA into colon cancer cells 94,95. Hiraki et al 94 identified miR-4689 as a TS-miRNA whose expression is downregulated by the lectively inhibited the proliferation of K-RAS mutant colon cancer cells.For selective delivery of miRNA, Orellana et al 96 developed a selective miRNA delivery system without vehicle.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Development of miRNA‐based therapeutic approaches for cancer patients

Takahashi

Prieto‐Vila

Kohama³

et al. 2019

Cancer Science

108

View full text Add to dashboard Cite

Over the past few decades, si RNA and mi RNA have attracted a great deal of attention from researchers and clinicians. These molecules have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes and cancers. si RNA suppresses only a single target, whereas each mi RNA regulates the expression of multiple target genes. More importantly, because mi RNA are also secreted from cancer cells, and their aberrant expression is associated with tumor development and progression, they represent not only therapeutic targets but also promising biomarkers for diagnosis and prognosis. Therefore, mi RNA may be more effective tools against cancers, in which multiple signal pathways are dysregulated. In this review, we summarize recent progress in the development of mi RNA therapeutics for the treatment of cancer patients, and describe delivery systems for oligonucleotide therapeutics.

show abstract

Section: Delivery System Of Mirnamentioning

confidence: 96%

Section: Delivery System Of Mirnamentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Development of miRNA‐based therapeutic approaches for cancer patients

Takahashi

Prieto‐Vila

Kohama³

et al. 2019

Cancer Science

108

View full text Add to dashboard Cite

show abstract

“…[11][12][13] Inoue et al reported that mir-29b-3p can inhibit the activity of colon cancer cells mutated by KRAS by inhibiting NF-κB signaling pathway. 14 Wang et al demonstrated that mir-29b can inhibit the growth and metastasis of colorectal cancer by downregulating the expression of Tiam1 and inhibiting epithelial-mesenchymal transformation. 13 Wang et al 11 found that mir-29b can inhibit the proliferation of pancreatic cancer cells by targeting DNMT3b.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-Small-Cell Lung Cancer A549/DDP Cells</p>

Jia¹,

Wang²

2020

CMAR

View full text Add to dashboard Cite

Objective: To investigate the expression of miR-29b-3p in tissues and cells of non-small-cell lung cancer (NSCLC) and its effect on cisplatin resistance in NSCLC cells and its mechanism. Methods: The mRNA expression of miR-29b-3p and COL1A1 in NSCLC tissue, cell line A549 and cisplatin-resistant cell line A549/DDP was detected by Mimics was transfected into A549/DDP cells, and the cell viability, proliferation, apoptosis and related protein expression were detected by CCK-8, flow cytometry and Western blot. Also, luciferase reporter gene assay was used to verify the targeting relationship between miR-29b-3p and COL1A1. Moreover, COL1A1 overexpression lentivirus and miR-29b-3p mimics (Mimics+COL1A1) were simultaneously transfected into A549/DDP cells, and then the cell viability and related protein expression were measured. Results: In NSCLC tissue and its cell line, miR-29b-3p was downregulated and COL1A1 was upregulated (P<0.05). After A549/DDP cell was transfected by mimics, its cell viability and proliferation rate decreased, apoptosis rate and the expression of tumor suppressor gene PTEN and apoptosis-related protein BAX were increased (P<0.05), which could be reversed by Mimics+COL1A1 co-transfection. Luciferase reporter gene assay indicated that COL1A1 was the target gene of miR-29b-3p. Conclusion: All in all, miR-29b-3p can reverse the cisplatin resistance of A549/DDP cells by inhibiting the expression of COL1A1 gene and increasing the expression of PTEN and BAX.

show abstract

“…miRNA expression profiles consist of determining different miRNA expression levels in multiple tumor samples (7). Previous studies have demonstrated that miRNA expression profiles are able to identify the tumor type, the staging and the other clinical characteristics, in addition to distinguishing between tumor and normal tissues, by which a variety of tumor and normal tissue samples may be analyzed systematically (8,9). The diagnostic accuracy rate of a tumor based on specific miRNA expression profiles is ≤70% (8).…”

Section: Introductionmentioning

confidence: 99%

miRNA‑29a inhibits colon cancer growth by regulation of the PTEN/Akt/GSK3β and Wnt/β‑catenin signaling pathways

et al. 2018

View full text Add to dashboard Cite

Abstract. In the present study, the effects of microRNA-29a (miRNA-29a) on colon cancer cell viability and the molecular mechanisms underlying the effects were investigated. The expression of miRNA-29a in colon cancer serum samples was notably downregulated, compared with in the normal group. First, miRNA-29a mimic was used to increase the expression of miRNA-29a in HCT-116 cells. Furthermore, upregulation of miRNA-29a suppressed cell viability, increased lactate dehydrogenase levels and apoptosis, and promoted caspase-3/9 activities and B-cell lymphoma 2-associated X protein and phosphatase and tensin homolog (PTEN) protein expression in colon cancer cells. Furthermore, upregulation of miRNA-29a decreased phosphoinositide 3-kinase, phosphorylated (p)-protein kinase B (Akt) and p-glycogen synthase kinase 3β (GSK3β) protein expression and suppressed the Wnt/β-catenin signaling pathway in colon cancer cells. The results of the present study verified that the protective effects of miRNA-29a suppress the PTEN/Akt/GSK3β and Wnt/β-catenin signaling pathways in colon cancer.

show abstract

A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells

Cited by 37 publications

References 52 publications

Development of miRNA‐based therapeutic approaches for cancer patients

Development of miRNA‐based therapeutic approaches for cancer patients

<p>MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-Small-Cell Lung Cancer A549/DDP Cells</p>

miRNA‑29a inhibits colon cancer growth by regulation of the PTEN/Akt/GSK3β and Wnt/β‑catenin signaling pathways

Contact Info

Product

Resources

About